))
Venture capital velocity: What’s driving renewed momentum in biotech?
Manage episode 427898376 series 2838531
Content provided by RBC Capital Markets. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by RBC Capital Markets or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
In biotech, a recovery is already well underway. Expected interest rate cuts and improving valuations across public and private markets are creating a compelling environment for deals, entrances, exits, and trades to take shape.
In this episode, biotech venture capital experts assess the sector’s sharper focus on funding fundamental science, evolving deal structures, including the return of reverse mergers and dual-track processes, and the key therapeutic modalities that are driving momentum in the market.
Hear from Andrew Aherrera, Partner at Panacea Venture; Jeni Lee, Partner at Pivotal Life Sciences; Regina Salvat, Principal at Sofinnova; and Noël Brown, Head of US Biotechnology Investment Banking at RBC Capital Markets, as they share their fresh perspectives on the dynamic forces propelling the biotech industry forward.
45 episoade
Distribuie
